Humira sales growth
Executive Summary
Sales of the TNF inhibitor grew 40 percent in the third quarter to $427 mil. in the U.S. compared to the year-ago period, Abbott reports. Humira (adalimumab), which recently underwent a successful launch for Crohn's disease, also gained share in the rheumatology, dermatology and gastroenterology markets (1"The Pink Sheet" July 23, 2007, p. 11). Worldwide Humira sales were $803 mil. in the quarter, up 48.5 percent from 2006, leading the company to predict 2007 sales of $3 bil. for Abbott's leading product. Overall, Abbott reports a 22.2 percent increase in global pharmaceutical sales and U.S. pharmaceutical sales rose 17.5 percent in the quarter...